Background: Vaccination against human papillomavirus (HPV) types 16/18 is being
implemented in many countries. There may be indirect benefit of HPV vaccination to …

Department of Obstetrics and Gynecology, University of Miami Miller School of Medicine,
Miami, FL h Abstract: The human papillomavirus (HPV) family causes a variety of benign …

Objective A vaccine against common high-risk types of human papillomavirus (HPV)
associated with cervical cancer risk was recently approved. We assessed women's …

Background: Cervical cancer incidence in the United States may be greatly reduced through
widespread human papillomavirus (HPV) vaccination. We estimated the statewide level of …

Background: The link between human papillomavirus (HPV) and anogenital cancers is well
established in the literature. Many states have passed laws requiring funding for HPV …

This policy brief looks at awareness and utilization of the Human Papillomavirus vaccine
among girls age 13 years and older as well as among young women. Interest in receiving …

PURPOSE: To assess availability of human papillomavirus (HPV) vaccine at medical
practices in an area with elevated cervical cancer rates. METHODS: During July–November …

In June 2006, the Food and Drug Administration (FDA) approved the first human
papillomavirus (HPV) vaccine. The vaccine was subsequently recommended by the Centers …

Objective. This study evaluates the degree to which medical school health insurance covers
the costs of the human papillomavirus (HPV) vaccine for medical students in the United …

The availability of a prophylactic human papillomavirus (HPV) vaccine for the prevention of
cervical cancer and its precursors offers the potential to reduce cervical cancer incidence …